Bioliberty Raises $10.2 Million in Series A Funding
Bioliberty, a healthtech company based in Edinburgh, Scotland, has successfully raised $10.2 million in a Series A funding round. The company focuses on developing technology to transform the delivery of physical and occupational therapy. This round of funding was led by the Scottish National Investment Bank, with participation from investors such as Archangels, Eos Advisory, Old College Capital, Hanna Capital SEZC, and Conduit Connect.
Company Overview
Bioliberty is known for engineering the future of physical and occupational therapy through its innovative use of AI and robotics. Their primary product, the Lifehub platform, is designed to improve patient outcomes in post-acute care settings by providing objective data on functional mobility. This data is crucial for reducing hospital readmissions and enhancing discharge planning.
Leadership and Vision
The company was co-founded by Ross O'Hanlon, who serves as the Chief Technology Officer, and Shea Quinn, the Chief Operating Officer. Their leadership has been pivotal in guiding Bioliberty's mission to fill significant gaps in healthcare by offering solutions that enable more accurate patient monitoring and therapy delivery.
Use of Funds
The newly acquired funds will be used to further develop Bioliberty's Lifehub platform, particularly focusing on expanding its computer vision capabilities and improving care coordination features. Additionally, the funding will support the commercialization of Lifehub in the U.S. market and the rollout of Lifehub Home, which extends therapy and monitoring into patients' homes.
Strategic Partnerships and Board Expansion
Bioliberty has established partnerships with major U.S. rehabilitation providers, including collaboration with one of the largest rehabilitation networks and the Sheltering Arms Institute. The company also works with research organizations such as Mount Sinai and the U.S. Department of Veterans Affairs. As part of the latest funding round, Bioliberty has expanded its board of directors, adding Russell Bailey, President of Lifepoint Rehabilitation, and Dana Prommel Strauss, Lead Director of Public Policy and Government Affairs at CVS Health.
Looking Ahead
With a total of $17.5 million raised since its inception in 2023, Bioliberty is well-positioned to continue its growth and innovation in the healthcare sector. The company's commitment to enhancing therapy delivery through advanced technology aligns with the increasing emphasis on value-based care models, where accurate measurement of patient function is vital.
For more information, visit Bioliberty's website.